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Purpose: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been proposed for 
controlling peritoneal seeding metastasis in some kinds of cancers, including those of colorectal origin, but their safety 
and oncological benefits are subjects of debate. We present our early experience with those procedures.
Methods: Data were retrospectively collected from all patients with peritoneal carcinomatosis (PC) and pseudomyxoma 
peritonei (PMP) treated using CRS and HIPEC at Yonsei Cancer Center between July 2014 and July 2015. Short-term out-
comes and risk factors for postoperative complications were analyzed. 
Results: Twenty-three patients with PC (n = 18) and PMP (n = 5) underwent CRS and HIPEC. Median follow-up and age 
were 2 months and 54 years, respectively. The median peritoneal carcinomatosis index score was 15, and CC0-1 was 
achieved in 78.3% of all patients. The median operation time and bleeding loss were 590 minutes and 570 mL, respec-
tively. Grade-IIIa/grade-IIIb complications occurred in 4.3% (n = 1)/26.1% (n = 6) of the patients within 30 days postop-
eratively, and no 30-day mortalities were reported. Factors related to postoperative complications with CRS and HIPEC 
were number of organ resection (P = 0.013), longer operation time (P < 0.001), and amount of blood loss (P = 0.003). All 
patients treated with cetuximab for recurred colorectal cancer had grade-III postoperative complication.
Conclusion: Our initial experience with CRS and HIPEC presented about 30% grade-III postoperative complications. There-
fore, expert surgeons need to perform those procedures with great caution in selected patients who might benefit from it.
Keywords: Cytoreduction Surgical Procedures; Peritoneal metastasis; Colorectal neoplasms; Pseudomyxoma peritonei 
INTRODUCTION
Peritoneal carcinomatosis (PC) is not an uncommon condition 
encountered in patients with colorectal cancer and, based on epi-
demiologic studies, is known to occur in approximately 10%–15% 
of all patients [1]. The median survival expectancy for patients 
with PC was reported to be about 7–8 months in untreated pa-
tients [2] and 12 months even in patients treated with systemic 
chemotherapy [3] until several centers worldwide reported favor-
able survival outcomes for patients treated using combined cyto-
reductive surgery (CRS) and hyperthermic intraperitoneal che-
motherapy (HIPEC). 
Even though the use of a combination of CRS and HIPEC in-
volves considerable risk of complications, as has been reported in 
several cohort studies and case series (29%–56%) [4-7], its effi-
cacy in selective patient groups is hardly in dispute. Verwaal [3] 
reported fascinating survival outcomes in their randomized con-
trolled trial: a median survival of 22.3 months and a significant 
risk reduction of dying (hazard ratio [HR], 0.55; 95% confidence 
interval [CI], 0.32–0.95; log-rank P = 0.032) in the HIPEC group 
in comparison to the systemic chemotherapy only group. More-
over, this substantial overall survival is likely to be amplified fur-
ther when patients to be treated using combined CRS and HIPEC 
are very carefully selected. Elias et al. [8], one of the leading 
groups using CRS and HIPEC, reported that patients with iso-
lated, resectable PC could prolong their median survival by up to 
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63 months with this aggressive procedure in comparison to a me-
dian survival of 24 months with modern chemotherapies. Sugar-
baker [9] insisted that a subset of patients with a peritoneal carci-
nomatosis index (PCI, which quantifies the intraperitoneal tumor 
burden by distribution and lesion size with a range of 0–39) less 
than 20 could profit in survival from his experience, and he em-
phasized the completeness of cytoreduction (CC 0–1) for the best 
survival outcome. 
Recently, some leading experts even asserted the necessity for 
using prophylactic HIPEC. They claimed that early peritoneal 
metastases are impossible to detect given the absence of symp-
toms and current limitations of imaging; therefore, proper timing 
of surgical intervention could be delayed. Indeed, some European 
centers are performing clinical randomized trials to demonstrate 
the role of prophylactic HIPEC in selective high-risk subgroups of 
patients with peritoneal recurrence [10]. 
In Korea, some centers have been performing combined CRS 
and HIPEC as an alternative treatment for patients with synchro-
nous or metachronous colorectal cancer with PC since HIPEC 
was first authorized as a new medical technology by the Ministry 
of Health and Welfare in late 2013. Even though HIPEC is being 
widely used for the treatment of PC in Western Europe and the 
United States, it is still known to involve high morbidity even at 
centers with experienced surgeons. Furthermore, HIPEC-related 
short-term outcomes in Korea are not available yet. Therefore, in 
this paper, we present and discuss our early experience related to 
HIPEC.
METHODS
Data were retrospectively collected from all patients with PC and 
pseudomyxoma peritonei (PMP) treated by using of combination 
of CRS and HIPEC at Yonsei Cancer Center between July 2014 
and July 2015. HIPEC was first introduced and conducted at our 
institution in July 2014. CRS was performed with intention-to-
treat in all patients for attaining R0-1 resections. Data were ana-
lyzed to demonstrate the safety of this procedure and the factors 
related with perioperative adverse events. 
Preoperative diagnosis and patient selection
All the patients referred to our clinic for CRS and HIPEC were 
thoroughly evaluated in order to exclude possible systemic metas-
tasis other than peritoneal seeding and to determine the tumor 
burden of PC and PMP. Diagnostic work-ups included esophago-
gastroduodenoscopy and colonoscopy, as well as computed to-
mography (CT) scans of the chest, abdomen and pelvis with IV 
contrast agents. Positron-emission tomography-CT (PET-CT) 
was considered if extra-abdominal metastasis was suspected or 
was difficult to determined based on the CT scans.
Patients with synchronous PC originating from colorectal can-
cer without systemic metastasis were mostly managed by using a 
combination of CRS and HIPEC, but patients with metachronous 
PC, which was incidentally detected by serial elevation of serum 
carcinoembryonic antigen (CEA) or on a CT scan during the fol-
low-up period after a curative resection, were initially considered 
as candidates for systemic chemotherapy. The cycles of preopera-
tive chemotherapy were left to the oncologist’s decision, but the 
resectability was discussed by the surgeon and the radiologist ev-
ery 4–6 cycles of chemotherapy. Also, if the patient requested 
other treatment options rather than chemotherapy or the oncolo-
gist judged continuation of chemotherapy to be impossible be-
cause of its toxicity and low patient compliance with the treat-
ment, a multidisciplinary team approach was recommended to 
the patient, the treatment plan was discussed further, and finally a 
decision was made to perform CRS and HIPEC when the tumor 
was such that a complete resection was thought to be possible, 
provided that the patient would benefit from the procedure. At 
out institution, PMP with obstructive symptoms or impending 
obstruction was considered to be an indication for the use of 
combined CRS and HIPEC.
Determination of CRS and HIPEC
Preoperative diagnostic laparoscopy was not routinely performed 
for the evaluation of resectability. Its use was entirely left to the 
surgeon. Mostly, the way to proceed for the CRS and HIPEC was 
decided under direct vision after a long midline abdominal inci-
sion had been made from the xiphoid process to the symphysis 
pubis. The extent of PC was determined at the time of initial sur-
gical exploration by using the PCI score. The PCI score, which 
was first suggested for the staging of PC by Jacquet and Sugar-
baker [11] in 1996 and which comprises 13 abdominopelvic re-
gions with lesion size scores and is a summed numerical score 
from 0 to 39, was adopted at our institution to investigate the ex-
tent of PC and to help surgeons determine how to apply the pro-
cedure. However, the indications for the use of CRS and HIPEC 
at our institution do not coincide with Sugarbaker [9]’s decision 
algorithm, but rather are based on those agreed on at a 2006 
HIPEC consensus meeting in Milano, Italy [12]. In other words, a 
combination of CRS and HIPEC is used when complete cytore-
duction is possible, regardless of the PCI score.
CRS and HIPEC procedure
CRS included removing the primary tumor with acceptable resec-
tion margins, metastatic lymph nodes, involved organs, and all 
peritoneal seeding metastases in the abdominopelvic cavity. If the 
tumors were unresectable because of anatomical location, includ-
ing mesenteries of the small and the large bowels, a high-voltage 
monopolar device was used for cauterization of multiple small le-
sions. A peritonectomy was not conducted in any of the patients; 
rather, a peritonectomy was performed if visual peritoneal seed-
ing metastases were confirmed at the initial surgical exploration. 
Before HIPEC was started, the completeness of cytoreduction 
(CC score from 0 to 3) [9] was measured and recorded.
HIPEC was facilitated using the open (coliseum) technique, 
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which was prepared by suturing 1-0 vicryl to the deep layer of the 
epidermis and subcutaneous area and fixing it to an Omni retrac-
tor with mosquito instruments. Initially, 3 L of heated perfusion 
solution was infused into the abdominal cavity at a rate of 600–
800 mL/min through the inflow tube by way of a Belmont hyper-
thermic pump. When the temperature of the abdominal cavity 
had reached 40°C–41°C, the first dose of mitomycin-C of 17.5 
mg/m2 was mixed into the heated solution, after which a dose of 
8.8 mg/m2 was added every 30 minutes. The temperature of the 
perfusion solution was maintained and evenly distributed at 
41°C–42°C by stirring with a surgeon’s hand. The duration of the 
HIPEC procedure was 90 minutes, after which the perfusion so-
lution was completely drained and a bowel anastomosis was per-
formed, if needed. All patients were taken to the intensive care 
unit for short-term observation. 
Postoperative chemotherapy and follow-up
Adjuvant chemotherapeutic regimens were mainly with FOLFOX 
(oxaliplatin, leucovorin and 5-FU) or FOLFIRI (irinotecan, leu-
covorin and 5-FU) with or without biologic agents. Postoperative 
chemotherapy was recommended for all patients after they had 
completely recovered from surgical stress without any complica-
tion.
After the completion of postoperative chemotherapy, clinical 
evaluations were performed regularly every 3 months for the first 
2 years and thereafter every 6 months for the subsequent 3 years. 
Serum CEA was measured whenever the patient visited the out-
patient clinic, and CT scans of the chest, abdomen and pelvis 
were performed every 6 months during the follow-up period. 
Statistical analysis
Patients were grouped according to the Clavien-Dindo classifica-
tion [13]. Group A, which was grades 0–II, included patients with 
mild complications without any need for further intervention, 
and group B, which was more than grade III, included patients 
with moderate-to-severe complication with need for surgical ex-
ploration or radiological/medical intervention. Each factor asso-
ciated with a postoperative complication after CRS and HIPEC 
Table 1. Case summary of CRS + HIPEC
Type No. Sex/age (yr) Origin PCI CC Complication
PC 1 M/48 Ascending colon cancer 20 0 Gastric stasis
2 F/47 Rectal cancer 22 1 Wound seroma
3 M/64 Cecal cancer 9 0 -
4 F/48 Ascending colon cancer 15 1 Wound seroma
5 F/47 Transverse colon cancer 16 1 -
6 M/72 Ascending colon cancer 3 0 -
7 M/37 Appendiceal cancer 9 0 -
8 F/54 Ovarian cancer 12 0 Pelvic abscess
9 M/43 Appendiceal cancer 28 2 -
10 M/39 Sigmoid colon cancer 2 0 Urinary retention
11 M/66 Ascending colon cancer 12 1 Intestinal obstruction
12 M/64 Cecal cancer 16 1 Postoperative bleeding
13 F/54 Ovarian cancer 6 0 -
14 M/63 Sigmoid colon cancer 4 0 -
15 M/62 Ascending colon cancer 10 1 Pleural effusion
16 F/50 Ascending colon cancer 30 2 -
17 M/69 Cecal cancer 13 1 -
18 F/36 Sigmoid colon cancer 17 1 -
PMP 1 F/61 Appendiceal cancer 39 2 Intestinal obstruction
2 M/60 Appendiceal cancer 24 2 Intestinal obstruction
3 M/67 Ascending colon cancer 13 1 Pleural effusion
4 M/63 Sigmoid colon cancer 28 2 Intra-abdominal abscess/Ileus
5 M/43 Appendiceal cancer 39 1 Anastomotic leakage
CRS + HIPEC, cytoreductive surgery + hyperthermic intraperitoneal chemotherapy; PC, peritoneal carcinomatosis; PMP, pseudomyxoma peritonei; PCI, peritoneal carcino-
matosis index; CC, completeness of cytoreduction.
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was divided into 2 groups by using the cutoff value from the re-
ceiver operating characteristic curve and was analyzed using the 
chi-square test. All P-values were two-sided, and P < 0.05 was 
considered statistically significant. All statistical analyses were 
carried out using the IBM SPSS Statistics ver. 20.0 (IBM Co., Ar-
monk, NY, USA).
RESULTS
A total of 23 patients with PC (n = 18) and PMP (n = 5) were 
considered for CRS and HIPEC with intention-to-treat (Table 1). 
The median follow-up period was 2 months (range, 0–11 
months), and the median age was 54 years old (range, 36–72 
years). Among these patients, 39.1% (n = 9) had an American So-
ciety of Anaesthesiologists physical status classification grade of 
more than III, and 13% (n = 3) were moderate-to-severe malnu-
trition status. All the patients with synchronous PC had a CRS 
and HIPEC without any neoadjuvant chemotherapy. However, 
patients with metachronous PC mostly had undergone preopera-
tive chemotherapy, a median of 12 cycles (range, 0–93 cycles) for 
24 months (range, 5–52 months), during the time from their last 
surgery until the CRS and HIPEC was performed (Table 2). 
The primary tumor origin of PC in patients with colorectal can-
cer was mostly the right-side colon (75%, 12 out of 16). The me-
dian PCI score was 15 (range, 2–39), and patients with PCI scores 
of more than 20 were included in this study (n = 7, 30.4%). Com-
plete cytoreduction was possible in 78.3% (n = 18) of the patients, 
but in 21.7% (n = 5) of the patients, the resection was an R2 resec-
tion. The median operation time and the bleeding loss were 590 
minutes (range, 350–1,225 minutes) and 570 mL (range, 80–3,250 
mL), respectively, and 9 patients (39.1%) required a transfusion 
during operation (Table 3).
Most patients recovered and were discharged a median of 19 
days (range, 8–101 days) after surgery. Adverse events during the 
first 30 days following surgery occurred in 12 (12 of 23, 52.2%) 
patients, and among those 12, 7 (7 of 12, 58.3%) needed further 
radiological intervention or surgical exploration. Moreover, late 
complications occurred in 2 of the 23 patients (8.7%), for whom 
delayed surgical intervention was needed. Therefore, overall 9 of 
the 23 patients (39.1%) who underwent CRS and HIPEC had 
more than grade-III complications according to the Clavien-
Dindo classification [13]. No mortalities occurred during the first 
30 days of the follow-up period, but disease-related deaths oc-
curred in 3 patients (13.0%) (Table 4).
Factors such as organs resected (more than 3), longer operation 
time (≥ 630 minutes), and large amount of blood loss (≥600 mL) 
during surgery were found to be associated with a high rate of 
postoperative complications. Interestingly, all 4 patients with re-
curred colorectal cancer who had been treated with cetuximab 
had grade-III postoperative complications. However, anastomotic 
leakage occurred in only 1 patient, who had a complete total col-
ectomy with ileorectal anastomosis and HIPEC because of PMP. 
Preoperative nutritional status and number of bowel anastomoses 
were not closely related to the occurrence of postoperative adverse 
events (Table 5).
DISCUSSION
Before HIPEC was permitted for the treatment of patients with 
colorectal cancer with PC in Korea, the only option for patients 
with PC was systemic chemotherapy with or without biologic 
agents. Even though newly developed chemotherapeutic and bio-
logic agents have prolonged the life expectancy in those patients 
[14], chemotherapy-related adverse events or intolerance and re-
sistance to this therapy ultimately made it impossible to prevent 
tumor progression and led to withdrawal of the treatment. 
Our institution initially had difficulty in enrolling patients for 
CRS and HIPEC because our oncologists and gastroenterologists 
had some suspicions about this new procedure with regards to its 
Table 2. Patient's characteristics (n = 23) 
Variable Value
Sex
   Male 15 (65.2)
   Female 8 (34.8)
Age (yr) 54 (36–72)
Preoperative PNIa
   Normal–mild (≥40) 20 (87.0)
   Moderate (35–40) 1 (4.3)
   Severe (<35) 2 (8.7)
Preoperative CEA level (ng/μL) 13.0 (2.0–141.0)
ASA physical status classification 
   I–II 14 (60.9)
   ≥III 9 (39.1)
PC timing
   Synchronous 7 (30.4)
   Metachronous 16 (69.6)
Time interval since last surgery (mo) 24 (5–52)
Neoadjuvant chemotherapy
   Yes 16 (69.6)
   No 7 (30.4)
Neoadjuvant chemotherapy cycles 12 (0–93)
Adjuvant chemotherapy 
   Yes 11 (47.8)
   No 12 (52.1)
Values are presented as number (%) or median (range).
CEA, carcinoembryonic antigen; ASA, American Society of Anaesthesiologists; PC, 
peritoneal carcinomatosis.
aPrognostic nutrional index (normal, ≥50; mild, 40–50; moderate, 35–40; severe, 
<35). 
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efficacy and safety. This distrust made them hesitate to introduce 
this new therapeutic option to their patients in whom the disease 
had been stabilized with continuous chemotherapy. The high 
complication rates previously reported in many centers world-
wide [4-7] and the existence of only a few randomized controlled 
trials were the main obstacles to persuading them to enroll their 
patients who were suffering from metachronous PC. Therefore, 
the first enrolled patient was one who had colorectal cancer with 
synchronous PC and who had been directly referred to our de-
partment by a local clinic. This patient was initially diagnosed 
with ascending colon cancer with a few peritoneal seeding nod-
ules based on the CT scan (PCI score, 8), but the intraoperative 
PCI score eventually revealed more than what had been expected 
preoperatively (intraoperative PCI score, 20). Even though this 
patient temporarily had gastric stasis, he recovered completely 
three weeks later and received adjuvant chemotherapy afterwards. 
He has shown no evidence of tumor recurrence since then. After 
the first patient had recovered without any major complication 
and HIPEC had been shown not to delay adjuvant chemotherapy, 
patients with metachronous PC started to be enrolled in HIPEC 
therapy by oncologists and gastroenterologists. As Tables 1 and 2 
show, not only patients with PC (n = 2) originating from other 
Table 3. Tumor characteristics and intraoperative parameters
Variable Value
Primary tumor
   Appendix 5
   Cecum 3
   Ascending colon 7
   Transverse colon 1
   Sigmoid colon 4
   Rectum 1
   Others 2
Histopathology
   Adenocarcinoma, well/moderately differentiated 12
   Adenocarcinoma, poorly differentiated/mucinous 9
   Serous cystadenocarcinoma (ovary origin) 2
Recurred tumor
   PC 18 (78.3)
      Right-sided colon cancer 12
      Left-sided colon cancer 4
      Ovarian cancer 2
   PMP 5 (21.7)
      Appendix origin 3
      Ascending colon 1
      Sigmoid colon 1
PCI score   
   ≤20 16 (69.6)
   >20 7 (30.4)
PCI score 15 (2–39)
CC score (n, %)
   0–1 18 (78.3)
   2–3 5 (21.7)
Completeness of resection
   R0 9 (39.1)
   R1 9 (39.1)
   R2 5 (21.7)
Operation time (hr) 590 (350–1,225)
Bleeding loss (mL) 570 (80–3,250)
Transfusion
   Yes 9 (39.1)
   No 14 (60.9)
Values are presented as number (%) or median (range).
PC, peritoneal carcinomatosis; PMP, pseudomyxoma peritonei; PCI, peirtoneal car-
cinomatosis index; CC, completeness of cytoreduction.
Table 4. Short-term outcomes after CRS + HIPEC (n = 23)
Variable Value
Follow-up (mo) 2 (0–11)
Hospital stay (day) 19 (8–101)
30 Days - AEa 12 (52.2)
   Grades I–II 5 (21.7)
   Grade IIIa 1 (4.3)
   ≥Grade IIIb 6 (26.1)
Postoperative IPC-related neutropenia 3 (13.0)
   Mild 2
   Moderate 1
   Severe 0
Late AEb 2 (8.7)
   Enterovaginal fistula 1
   Intestinal obstruction  1
30 Days - mortality 0
Postoperative disease status 
   No recurrence or stable disease 18 (65.2)
   Recurrence or progression of disease 5 (34.8)
Death during follow-up 3 (13.0)
   Disease related 3
   Disease unrelated 0
Values are presented as median (range) or number (%).
CRS + HIPEC, cytoreductive surgery + hyperthermic intraperitoneal chemother-
apy; IPC, intraperitoneal chemotherapy. 
aAE, adverse event according to the Clavien-Dindo classification. bLate AE: compli-
cations 30 days after CRS + HIPEC.
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sites such as the ovaries but also patients with PMP (n = 5) were 
included in the analysis because the main purpose of our study 
was to introduce our early experiences with respect to the safety 
of this new procedure in a single center. 
As for HIPEC-associated complications, 3 adverse events (3 of 7, 
14.3%), urinary retention, gastric stasis, and intestinal obstruc-
tion, occurred in patients with synchronous PC, and the patient 
with intestinal obstruction was eventually treated with surgical in-
tervention. To be frank, this patient was the first and the last pa-
tient enrolled in HIPEC despite his having a nonprogressive single 
hepatic metastasis after completion of 12 cycles of neoadjuvant 
chemotherapy, which is known to be a contraindication for 
HIPEC. During a 660-minute surgery, CRS and intraoperative ra-
dio-frequency ablation to a single hepatic metastasis were per-
formed, attaining a R0 resection. Among 16 patients with meta-
chronous PC or PMP, 9 patients (56.3%) had postoperative com-
plications within 30 days. Excluding 3 patients with minor adverse 
events, 6 other patients with major complications (37.5%), such as 
intra-abdominal abscess, pleural effusion, intestinal obstruction, 
immediate postoperative bleeding and anastomotic leakage, were 
finally treated with radiologic or surgical interventions. 
Given our short-term outcomes, the major complication rate for 
patients with synchronous PC tended to be lower than it was for 
patients with metachronous PC. This is the reason patients with 
metachronous PC commonly present with conditions that are 
unfavorable for surgery, including severe adhesion, undernutri-
tional status and previous multiple cycles of chemotherapy with 
or without biologic agents. As Table 5 shows, all 4 patients treated 
with cetuximab preoperatively had major complications, such as 
pleural effusion, intestinal obstruction, immediate postoperative 
bleeding and intra-abdominal abscess with sepsis. In a recent Eu-
ropean study, bevacizumab was also found to be associated with a 
twofold increased morbidity in patients treated with CRS and 
HIPEC (odds ratio, 2.28; 95% CI, 1.05 to 4.95; P = 0.04) [15]. 
Therefore, great attention is needed when performing CRS and 
HIPEC, particularly in the patients who have metachronous PC 
or have received preoperative chemotherapy or biologic therapy.
In addition to the aforementioned preoperative unfavorable 
conditions, the major complications tended to be associated with 
several intraoperative factors, as shown in Table 5. Major compli-
cations occurred more commonly in patients who had more than 
3 organs resected, operation times of 630 minutes or longer, and 
losses of 600 mL or more of blood during surgery. Against our ex-
pectation, anastomotic leakage occurred in only one patient 
(4.3%) and showed no significant differences compared to usual 
colorectal surgery. A great diversity of opinion exists concerning 
this early postoperative major complication rate (7 of 23, 30.4%), 
i.e., whether it needs to be abided for better oncologic outcomes 
or not. However, if we can attain the same oncologic outcomes as 
leading experts in Europe and the United States do, we think this 
aggressive procedure, with its accompanying high morbidity, 
should be considered for carefully selected patients who might 
Table 5. Factors associated with postoperative complications after 
CRS + HIPEC
Variable
Group A 
(n = 14)
Group B
(n = 9)
P-value
Agea 0.214
   <55 9 (64.3) 3 (33.3)
   ≥55 5 (35.7) 6 (66.7)
Body mass index (kg/m2) 0.197
   <21 6 (42.9) 7 (77.8)
   ≥21 8 (57.1) 2 (22.2)
No. of organs resected 0.013
   0–2 11 (78.6) 2 (22.2)
   ≥3 3 (21.4) 7 (77.8)
No. of bowel anastomosis 0.391
   0–2 14 (100) 8 (88.9)
   ≥3 0 (0) 1 (11.1)
Previous operation 0.176
   No 6 (42.9) 1 (11.1)
   Yes 8 (57.1) 8 (88.9)
PCI indexa 0.214
   <15 9 (64.3) 3 (33.3)
   ≥15 5 (35.7) 6 (66.7)
ASA score 0.999
   1–2 9 (64.3) 5 (55.6)
   ≥3 5 (35.7) 4 (44.4)
Operation time (min)a < 0.001
   <630 12 (85.7) 0 (0)
   ≥630 2 (14.3) 9 (100)
Blood loss (mL)a 0.003
   <600 11 (78.6) 1 (11.1)
   ≥600 3 (21.4) 8 (88.9)
Transfusion 0.077
   No 11 (78.6) 3 (33.3)
   Yes 3 (21.4) 6 (66.7)
Cycles of preoperative chemotherapya 0.383
   <17 10 (71.4) 4 (44.4)
   ≥17 4 (28.6) 5 (55.6)
Preoperative biologic agent 0.017
   None 11 (78.6) 5 (55.6)
   Cetuximab 0 (0) 4 (44.4)
   Avastin 2 (14.3) 0 (0)
   Avastin + cetuximab 1 (7.1) 0 (0)
Preoperative PNIb 0.538
   Normal–mild 13 (92.9) 7 (77.8)
   Moderate–severe 1 (7.1) 2 (22.2)
CRS + HIPEC, cytoreductive surgery + hyperthermic intraperitoneal chemotherapy.
Group A, Clavien-Dindo classification grades 0–II; group B, Clavien-Dindo classifi-
cation grade ≥ III.
aCutoff value obtained from the receiver operating characteristic curve. bPrognos-
tic nutrional index (normal, ≥50; mild, 40–50; moderate, 35–40; severe, <35).
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benefit from it use.
In conclusion, our initial experience with CRS and HIPEC 
showed that about 30% of the patients experienced grade-III 
postoperative complications, which was strongly associated with 
the number of organs resected, longer operation time, and the 
amount of blood loss. Therefore, an expert surgeon needs to per-
form this combined procedure with great caution and only on se-
lected patients who might benefit from it.
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